Vektor applies for approval of EpiVacCorona-N jab

Russia’s Vektor State Research Center of Virology and Biotechnology has applied for the Russian Ministry of Health’s approval of its EpiVacCorona-N vaccine, the ministry’s website revealed on Monday.

Vektor Center’s General Director Rinat Maksyutov previously explained that there are no significant differences between the COVID-19 jab and EpiVacCorona vaccine, apart from the technological aspects of productions.

Russia’s second-registered coronavirus vaccine provides a one-year immunity, according to the center’s earlier announcement.

Breaking the News / BU